Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths — agonizing, from diseases or infections the body might otherwise fight off — sent loved ones into the streets ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A generation has passed since the world saw ...
A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths -- agonizing, from diseases or infections the body might otherwise fight off -- sent loved ones into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback